AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of “Moderate Buy” from Analysts

AbbVie Inc. (NYSE:ABBV) has received an average recommendation of “Moderate Buy” from the twenty-four analysts that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $245.8421.

ABBV has been the topic of a number of recent analyst reports. UBS Group boosted their price objective on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. BMO Capital Markets increased their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Evercore ISI raised their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock.

Institutional Investors Weigh In On AbbVie

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of AbbVie in the second quarter valued at about $4,288,200,000. Wellington Management Group LLP boosted its holdings in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC grew its position in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.5%

NYSE:ABBV opened at $228.55 on Friday. The stock’s 50-day moving average is $226.66 and its 200-day moving average is $213.48. AbbVie has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market cap of $403.94 billion, a P/E ratio of 173.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.